Effect of icatibant on sweating-induced dermal pain
BackgroundExposure to sweating stimuli triggers transient and severe dermal pain in certain individuals. This study aimed to evaluate the analgesic effect of icatibant, a bradykinin B2 receptor antagonist, for the dermal pain induced by sweating stimuli and explored the role of bradykinin in its pat...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Journal of Cutaneous Immunology and Allergy |
| Subjects: | |
| Online Access: | https://www.frontierspartnerships.org/articles/10.3389/jcia.2025.14276/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | BackgroundExposure to sweating stimuli triggers transient and severe dermal pain in certain individuals. This study aimed to evaluate the analgesic effect of icatibant, a bradykinin B2 receptor antagonist, for the dermal pain induced by sweating stimuli and explored the role of bradykinin in its pathomechanism.MethodsThis single-blind, randomized, crossover study enrolled adult patients who had experienced severe sweating-induced dermal pain. Participants randomly received icatibant (30 mg) or placebo on Day 1 and vice versa on Day 2. Before and after drug administration, dermal pain induced by an artificial thermal loading was assessed using the visual analog scale (VAS).ResultsFour patients were enrolled, three of whom completed the full procedure with the termination in the other. Among the three patients, the pain-VAS score decreased more with icatibant than with saline in one patient, whereas it decreased more with saline than with icatibant in the other two patients. The pain duration decreased more with icatibant than with saline in two patients, whereas it decreased equally with both treatments in the other. Icatibant did not affect the changes in whole blood and plasma histamine, and serum angiotensin-converting enzyme levels after the induction of the dermal pain. A safety profile showed injection site pain associated with icatibant.ConclusionBlockade of bradykinin B2 receptor signaling by icatibant contributed to the reduction of dermal pain during sweating stimuli in one patient but not in two others. The role of bradykinin in the dermal pain varies among patients.Clinical trial registrationhttps://jrct.niph.go.jp/, identifier jRCTs061210021. |
|---|---|
| ISSN: | 2574-4593 |